IN BRIEF: Diaceutics shares surge on contract win with top US firm

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Diaceutics PLC - Belfast-based testing laboratories company - Wins a three-year enterprise contract with an unnamed ‘top 10 global pharmaceutical company’ based in the US. Says the contract will bring in $10.1 million in revenue over its term, with options to ‘significantly’ increase its scope and value. Revenue will be recognised monthly, with immediate effect. Says revenue will be recognised on a monthly basis. It will deliver a range of subscription data services via its DXRX platform.

Chief Innovation Officer Ryan Keeling says: ‘The strength of our growing pipeline of new enterprise-level contracts highlights the progress made in becoming the primary commercialisation partner for pharma or biotech companies launching a new precision medicine.’

Current stock price: 91.50 pence each, up 14% on Monday morning in London

12-month change: down 17%

Copyright 2023 Alliance News Ltd. All Rights Reserved.